Inhibition of PI3K/mTOR pathways with GDC-0980 in pediatric leukemia: Impact on abnormal FLT-3 activity and cooperation with intracellular signaling targets.

CONCLUSION: These findings provide initial proof-of-concept data and rationale for further investigation of GDC-0980 in selected subgroups of pediatric leukemia patients. PMID: 30914027 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30914027?dopt=Abstract

Source: Current Cancer Drug Targets - March 25, 2019 Category: Cancer & Oncology Authors: Al-Ghabkari A, Perinpanayagam MA, Narendran A Tags: Curr Cancer Drug Targets Source Type: research

More News: Cancer | Cancer & Oncology | Leukemia | Pediatrics | Study